Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -114.75M | -107.19M | -99.03M | -101.80M | -119.47M |
| Total Depreciation and Amortization | -5.28M | 2.27M | 1.94M | 2.16M | 2.18M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.76M | 15.43M | 14.02M | 1.83M | 12.79M |
| Change in Net Operating Assets | 10.56M | 30.35M | -8.16M | -15.81M | 5.85M |
| Cash from Operations | -83.72M | -59.14M | -91.22M | -113.62M | -98.66M |
| Capital Expenditure | -5.09M | -3.88M | -4.79M | -2.15M | -2.24M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 177.30M | 97.54M | 103.36M | -451.04M | 75.28M |
| Cash from Investing | 172.21M | 93.66M | 98.57M | -453.19M | 73.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.32M | -24.02M | -- | -- | -- |
| Issuance of Common Stock | 4.16M | 5.94M | 6.76M | 500.28M | 4.71M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -480.00K | -- | -- | -- |
| Cash from Financing | -4.17M | -18.56M | 6.76M | 500.28M | 4.71M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 84.32M | 15.96M | 14.11M | -66.53M | -20.91M |
